Angelalign Technology (6699) is a CN-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of HK
3.6B, trading at HK$79.70 on the HKSE. This SniperIQ fundamentals page covers Angelalign Technology's valuation (P/E 57.4x, P/B 3.4x), profitability (net margin 7.7%), revenue (¥2.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapHK
3.6B
P/E (TTM)57.4x
Net Margin7.7%
Revenue (FY25)¥2.6B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Angelalign Technology's market cap?
Angelalign Technology (6699) has a market capitalization of approximately HK
3.6B, trading at HK$79.70 on the HKSE. Market cap moves with the live share price.
What is Angelalign Technology's P/E ratio?
Angelalign Technology's trailing twelve-month P/E ratio is 57.4x, with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Angelalign Technology?
Angelalign Technology runs a net profit margin of 7.7%, a gross margin of 62.9%, and an operating margin of 8.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Angelalign Technology generate?
Angelalign Technology reported revenue of ¥2.6B for fiscal year 2025, with net income of ¥199M and earnings per share (EPS) of 1.18. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Angelalign Technology pay a dividend?
Angelalign Technology offers a trailing dividend yield of about 7.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Angelalign Technology financially healthy?
Angelalign Technology carries a debt-to-equity ratio of 0.00x and a current ratio of 2.98x, with a market beta of 1.19. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Angelalign Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Angelalign Technology (6699) the key facts are: market cap HK
3.6B, P/E 57.4x, revenue ¥2.6B, 52-week range 52.8-94.9. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Angelalign Technology's full fundamentals live
Get Angelalign Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.